CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts
A Cancer Drug Looks Even Better
By

(FORTUNE Magazine) – Dramatic successes with Interleukin-2, an experimental drug that bolsters the body's ability to destroy cancer cells, seemed to signal a breakthrough in cancer research (FORTUNE, November 25, 1985). Two follow-up studies published in April show the early results were not flukes. In a National Cancer Institute project, the drug shrank tumors at least 50% in 29 of 157 patients for whom previous treatment had been either impossible or unsuccessful. The cancers disappeared, at least temporarily, in nine of these patients. Says Frank Rauscher Jr., director of research for the American Cancer Society: ''We've proven that biologic response modifiers like IL-2 and interferon are life-saving -- certainly for the short term.''